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Abstract
Background: Recent studies have questioned our previous understanding on the effect of nitrous oxide on muscle
relaxants, since nitrous oxide has been shown to potentiate the action of bolus doses of mivacurium, rocuronium
and vecuronium. This study was aimed to investigate the possible effect of nitrous oxide on the infusion
requirements of cisatracurium.
Methods: 70 ASA physical status I-III patients aged 18-75 years were enrolled in this randomized trial. The patients
were undergoing elective surgery requiring general anesthesia with a duration of at least 90 minutes. Patients were
randomized to receive propofol and remifentanil by target controlled infusion in combination with either a mixture
of oxygen and nitrous oxide (Nitrous oxide/TIVA group) or oxygen in air (Air/TIVA group). A 0.1 mg/kg initial bolus
of cisatracurium was administered before tracheal intubation, followed by a closed-loop computer controlled
infusion of cisatracurium to produce and maintain a 90% neuromuscular block. Cumulative dose requirements of
cisatracurium during the 90-min study period after bolus administration were measured and the asymptotic steady
state rate of infusion to produce a constant 90% block was determined by applying nonlinear curve fitting to the
data on the cumulative dose requirement during the study period.
Results: Controller performance, i.e. the ability of the controller to maintain neuromuscular block constant at the
setpoint and patient characteristics were similar in both groups. The administration of nitrous oxide did not affect
cisatracurium infusion requirements. The mean steady-state rates of infusion were 0.072 +/- 0.018 and 0.066 +/-
0.017 mg * kg-1 * h-1 in Air/TIVA and Nitrous oxide/TIVA groups, respectively.
Conclusions: Nitrous oxide does not affect the infusion requirements of cisatracurium.
Trial registration: ClinicalTrials.gov NCT01152905; European Clinical Trials Database at http://eudract.emea.eu.int/
2006-006037-41.
Background
Volatile anesthetics are known to affect the pharmaco-
dynamics of neuromuscular blocking agents [1-3]. For
this reason neuromuscular blocking agents are usually
studied under nitrous oxide anesthesia supplemented
with opioids and intravenous hypnotics. Unlike volatile
anesthetics, nitrous oxide has been thought to have no
effect on the dose-response relation of neuromuscular
blocking drugs.
However, recent studies have questioned our previous
understanding on the effect of nitrous oxide on muscle
relaxants since nitrous oxide has been shown to
potentiate the action of bolus doses of mivacurium,
rocuronium and vecuronium [4-6]. Whether this inter-
action is due to an alteration in pharmacokinetics or
pharmacodynamics remains, however, completely
unknown. Evidence from one study on the infusion
requirements of rocuronium during nitrous oxide
demonstrated that nitrous oxide does not affect rocuro-
nium in a clinically significant degree [7]. Thus, different
study methodology appears to give different results on
the interaction between nitrous oxide and rocuronium.
Because the mechanism of action of nitrous oxide on
muscle relaxants is unknown and because it is contro-
versial whether there is an interaction between nitrous
oxide and muscle relaxants, we found it important to
repeat our previous study [7] using cisatracurium, a
muscle relaxant with a different chemical structure and
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aminosteroid relaxant rocuronium, is a benzyl isoquino-
line compound with a novel pharmacokinetic profile
since its elimination kinetics is essentially independent
of liver and renal function [8]. We used a closed-loop
feedback control method of administering cisatracurium
to maintain a constant neuromuscular block of 90%.
The interaction between cisatracurium and nitrous
oxide was measured by determining the infusion
requirements to produce 90% neuromuscular block with
cisatracurium.
Methods
This study was performed in accordance with the Good
Clinical Research Practice Guidelines for pharmacody-
namics studies of neuromuscular blocking agents [9].
After obtaining approval by the ethics committee of the
Hospital District of Southwest Finland to conduct the
study, 70 patients providing informed written consent
were enrolled. We used a randomized study design in
parallel groups. Based upon previous studies [3] it was
calculated that 35 patients would be required in each
group to establish a 15% difference in cisatracurium
requirements at a level of significance of P =0 . 0 5a n da
power of 80%. The patients were aged 18-75 years, their
ASA physical status 1-3, and they were scheduled to
undergo elective surgery requiring general anesthesia
with a duration of at least 90 minutes. Patients with sig-
nificant renal, hepatic or cardiac disease were excluded
from the study, as were patients with raised intracranial
pressure, a body mass index greater than 32.5 kg/m
2,
patients suffering from neurologic disease or receiving
medication known to affect neuromuscular function.
The patients received oral premedication consisting of
3.75-7.5 mg midazolam approximately 1 hour prior to
induction of anesthesia. All patients received total intra-
venous anesthesia (TIVA) using target controlled infu-
sion of propofol and remifentanil. One group of patients
received a mixture of air with 30% oxygen (Air/TIVA
group) and the other group received nitrous oxide with
30% oxygen (Nitrous oxide/TIVA group). The patients
were randomly assigned to one of these groups, each
group consisting of 35 patients. The initial target of pro-
p o f o lw a ss e ta t4μg/ml and if necessary adjusted to 6
μg/ml for adequate induction. After induction the target
was maintained at 4 μg/ml until the end of surgery. The
target of remifentanil was initially set at 2 ng/ml and
later adjusted between 1.5-6 ng/ml, according to clinical
needs. A decrease in systolic blood pressure below 85
mmHg or a decrease in mean blood pressure below 55
mmHg, respectively, was treated by decreasing the target
of remifentanil to a minimum level of 1.5 ng/ml. In
addition, the patients received rapid infusion of Ringer’s
acetate solution and/or 5-10 mg of intravenous
ephedrine, when considered necessary. In hypertensive
patients treatment of hypotension was initiated if a 30%
decrease in blood pressure was detected. Fresh gas flow
was kept at 10 l/min until tracheal intubation, using the
above mentioned gas mixtures. During maintenance of
anesthesia gas flow was set at 5 l/min, with the end-
tidal nitrous oxide concentration kept above 65% in the
patients receiving nitrous oxide.
The degree of neuromuscular blockade was assessed
every 20 seconds, throughout the procedure, using a
Datex Relaxograph® monitor (Datex, Helsinki, Finland).
Surface electrodes were attached over the ulnar nerve
and over the first interosseus muscle and the index fin-
ger [10]. The train-of-four sequence was used (2 Hz fre-
quency, 100 ms pulse width), the stimulus output being
a rectangular wave with a current of 0-70 mA. The
machine calibrated automatically by searching for the
optimal signal levels before setting the supramaximal
level. Control electromyographic values were obtained
after induction and following this, a stable baseline cali-
bration signal was awaited and a second calibration was
performed approximately 10 minutes after induction of
anesthesia. During this period patients were ventilated
manually with a mask. The degree of neuromuscular
blockade was defined as the ratio of the measurement
of the first twitch in the train-of-four sequence to the
corresponding control value.
After obtaining a stable calibration signal, a bolus dose
of 0.1 mg/kg cisatracurium was administered. We used
the ideal body weight (IBW), as defined by Devine’s
equation, for the calculation of the dose of cisatracurium
[11]. Tracheal intubation was performed and the
patients were mechanically ventilated using either of the
above mentioned gas mixtures. Bolus administration of
cisatracurium was followed by infusion of cisatracurium
by a model-driven closed-loop feedback system as
described previously [12]. An infusion pump (Fresenius
Infusomat CP®; Bad Homburg, Germany) and the Relax-
ograph® were attached to a Compaq® portable 386 com-
puter (Houston, TX) by means of a serial RS232C
interface. The study time was 90 min for all patients.
Propofol, remifentanil, and cisatracurium infusions were
continued as long as clinically indicated, but only the
initial 90-min period from the administration of the
bolus dose of cisatracurium was analyzed. Palmar skin
temperature was measured and kept above 33°C, and
end-tidal carbon dioxide was maintained at 34-40 mm
Hg (4.5-5.3%). Depth of anesthesia was monitored using
the Bispectral Index.
The desired level of neuromuscular block (i.e., the set
point) was set to 90% (the first twitch in the train-of-
four sequence = 10% from control). Controller perfor-
mance was measured by calculating the mean offset
from set-point and the mean SD from set-point during
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values for effect and rate of the infusion were saved on
the computer. The possible effect of nitrous oxide on
the infusion requirements of cisatracurium was quanti-
fied by comparing the asymptotic steady state rates of
infusion for 90% block between the groups. To estimate
the asymptotic steady state rates of infusion, we used
nonlinear curve fitting for the cumulative dose curve of
cisatracurium during the 90-min study period [13].
Cumulative dose of cisatracurium D e I t
kt
ss =⋅− +
− () , 1
where D is the amount of cisatracurium in its appar-
ent distribution volume, k is the relative rate of distribu-
tion of cisatracurium, Iss is the asymptotic steady state
infusion rate of cisatracurium, and t is the duration of
administration of cisatracurium. The asymptotic steady
state rates of infusion were given as actual values and
per kilogram ideal body weight (Iss/IBW). By the end of
surgery, all patients received a neostigmine-glycopyrro-
late mixture to reverse neuromuscular block according
to our normal routine.
For statistical analysis, we used the Student t test and
chi-square test. P < 0.05 was considered to indicate sta-
tistically significant differences between the two groups.
All results are given as mean ± SD. For continuous vari-
ables, we also calculated 95% confidence intervals of the
differences in mean values. All data were analyzed with
use of the statistical programS y s t a tf o rW i n d o w s ,v e r -
sion 10.2 (Systat Software, Richmond, CA).
Registration
ClinicalTrials.gov NCT01152905; European Clinical
Trials Database at http://eudract.emea.eu.int/2006-
006037-41
Results
Patient characteristics, controller performance and
values for the cumulative dose of cisatracurium during
the 90-min study period, Iss and Iss/IBW, are shown in
Table 1. No statistically significant differences in patient
characteristics or controller performance were observed
in the two groups. The values for the average duration
of infusion of cisatracurium in the two groups (55.6 ±
7.6 min in the Nitrous oxide/TIVA group and 58.5 ±
6.1 min in the Air/TIVA group) did not differ. Periph-
eral skin temperature, end-tidal carbon dioxide, average
values for Bispectral Index and remifentanil consump-
tion were also similar. Average Bispectral Index levels
were 27.7 ± 6.3 in the Nitrous oxide/TIVA group and
30.2 ± 8.4 in the Air/TIVA group, respectively (P =
0.163), while the average cumulative doses of remifenta-
nil were 524 ± 132 μg and 585 ± 163 μg, respectively
(P = 0.091). There was a tendency for slightly more
frequent ephedrine administration in the Nitrous oxide/
TIVA group, but the difference was not statistically sig-
nificant. Figure 1 shows an example of the time course
of neuromuscular block and the cumulative dose
requirements of cisatracurium for one representative
patient in the Nitrous oxide/TIVA group. The cumula-
tive dose of cisatracurium, Iss and Iss/IBW did not differ
(Table 1 and Figure 2).
Discussion
The computerized closed-loop feedback infusion of cisa-
t r a c u r i u mk e p tt h el e v e lo fn e u r o m u s c u l a rb l o c ka ta
reasonably constant level and thus allowed the accurate
quantitation of the possible interaction of nitrous oxide
with cisatracurium by assessing cisatracurium infusion
requirements. Unlike observed earlier with bolus admin-
istration of mivacurium, rocuronium and vecuronium
[4-6] but in good agreement with our own study with
continuous infusion of rocuronium, nitrous oxide had
no statistically significant effect on cisatracurium
although the study was adequately powered to observe
as small as 15% difference in infusion requirements at a
level of significance of P = 0.05 and a power of 80%.
Our studies differ from previous studies on the inter-
action between nitrous oxide and muscle relaxants in
many ways. Like our former study on rocuronium [7]
but unlike previous studies using bolus techniques, we
used a closed-loop feedback control method of adminis-
tering cisatracurium to produce and maintain a rela-
tively constant neuromuscular block of 90%. It was thus
possible to quantitate any interaction between cisatra-
curium and nitrous oxide during maintenance of
anesthesia with longer exposure to nitrous oxide and
with minimal disturbance of the clinical routine. It has
been suggested that propofol may affect the potency of
neuromuscular blocking drugs. In one study a 20-min
infusion of propofol caused a 50% rise in the potency of
mivacurium as compared to a 5-min propofol infusion
[14]. We used a target controlled infusion of propofol
and the target was kept unchanged at 4 μg/ml in each
patient during the maintenance of anesthesia for the
entire study period. Because remifentanil is not known
to affect the level of neuromuscular blockade [15] and
because its cumulative dose during the 90-min study
period and BIS-levels were similar in both groups, we
believe that we were able to quantitate the effect of
nitrous oxide on cisatracurium.
If the possible interaction of nitrous oxide and muscle
relaxants is studied using bolus techniques, it has several
implications. The study group of Kopman et al. [5] used
the single-dose technique for the quantition of the
nitrous oxide-rocuronium interaction. They estimated
the value of the mean effective dose 50% (ED50) assum-
ing that the dose-effect relation of rocuronium has a
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decrease of the mean ED50 was observed. Although this
technique has weaknesses, it provides a rather robust
estimate of the ED50, but with wide confidence intervals.
If the true value of the slope were, for instance, 3.5 the
estimate for the ED50 w o u l di n c r e a s eb ya p p r o x i m a t e l y
3%. The value of 5.5 would decrease ED50 by 1%. The
single-dose technique can be used to estimate ED95, too.
However, such calculations are seldom done because
they are much more sensitive for having the correct
value of the log-dose/logit slope. However, one might
question the usefulness of ED50 for clinical purposes
where normally at least 90% neuromuscular block is
required for adequate surgical relaxation. We thus
Table 1 Steady-state rate of infusion of cisatracurium controlled by closed-loop feedback system to maintain
neuromuscular blockade constant at 90% during total intravenous anesthesia (TIVA) with air (Air/TIVA) or with nitrous
oxide (Nitrous oxide/TIVA)
Patients Controller
performance
Time to 10% recovery of T1
following the initial bolus
(min)
Cumulative dose of
cisatracurium/IBW
(mg/kg)
Steady-state
rate of
infusion of
cisatracurium
Group No.
(M/
F)
ASA
(1/
2/3)
Age
(yr)
Weight
(kg)
Height
(cm)
Offset
from
set-
point
(%)
SD from
set-point
(%)
Iss
(mg/
h)
Iss/IBW
(mg·kg
-
1·h
-1)
Air/TIVA 35
(20/
15)
23/
12/0
47.3
±
12.6
75.0 ±
14.3
173 ±
11
0.96 ±
1.25
3.03 ± 1.34 31.5 ± 6.1 12.4 ± 2.6 4.8 ±
1.5
0.072 ±
0.018
Nitrous
oxide/TIVA
35
(22/
13)
18/
16/1
48.6
±
12.3
77.7 ±
15.1
174 ±
10
1.10 ±
1.28
2.95 ± 1.19 34.4 ± 7.6 12.1 ± 2.2 4.5 ±
1.2
0.066 ±
0.017
Mean
difference
(95% CI)
1.3
(-4.7,
7.2)
2.7
(-4.3,
9.7)
1.3
(-3.8,
6.3)
0.14
(-0.47,
0.74)
-0.08
(-0.68, 0.53)
2.9
(-0.4, 6.2)
0.3
(-1.5, 0.8)
-0.3
(-1.0,
0.3)
-0.005
(-0.014,
0.003)
Values are mean ± SD. There were no statistically significant differences between the groups.
ASA = American Society of Anesthesiologists physical status classification; CI = confidence interval of the difference in mean values; IBW = ideal body weight; Iss
= asymptotic steady-state rate of infusion; Iss/IBW = asymptotic steady-state rate of infusion per kg ideal body weight; NMB = neuromuscular blockade; SD =
standard deviation; T1 = first twitch in the train-of-four sequence.
Figure 1 Neuromuscular block and rate of infusion of cisatracurium. Data for one representative patient in the Nitrous oxide/TIVA (total
intravenous anesthesia) group showing the rate of infusion (Iss) necessary to produce a constant 90% neuromuscular (NM) block by closed-loop
infusion of cisatracurium, the corresponding cumulative dose requirements of cisatracurium, the fitted cumulative dose requirements and the
measured NM block.
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interaction of nitrous oxide and muscle relaxants using
constant infusion of the muscle relaxant under
investigation.
Other previous studies using bolus techniques in the
assessment of the pharmacodynamics have yielded simi-
lar results as compared to Kopman et al. [5] Nitrous
oxide has been shown to slightly affect the potency of
both vecuronium [6] and mivacurium [4]. However, the
duration of nitrous oxide administration before muscle
relaxant was only 15 min in these rocuronium and
mivacurium studies and 5 min in the vecuronium study
[4-6]. While the interaction between muscle relaxants
and volatile anesthetics is clearly a pharmacodynamic
one, the mechanism of action of nitrous oxide on neu-
romuscular blocking drugs is still unknown. Volatile
anesthetics do not seem to affect the pharmacokinetics
of muscle relaxants, and it is generally assumed that
nitrous oxide has no effect on the pharmacokinetics of
muscle relaxants [16-20]. It has been proposed that
nitrous oxide affects the neuromuscular junction directly
and independently of its rate of accumulation in the
muscle [4] or by altering the transfer of muscle relaxants
to the site of action [5]. In fact the saturation of muscle
tissue with nitrous oxide is less than 30% complete after
15 min of nitrous oxide anesthesia thus supporting the
idea of an accumulation-independent effect of nitrous
oxide on neuromuscular junction [4].
The reason for the disagreement between both our
studies using continuous infusion and previous studies
using bolus administration of muscle relaxants [4-6] is
not at all clear. Obviously, the results of our studies
cannot be directly compared to the previous studies,
due to this difference in modes of administration. Ide-
ally, the effect of anesthesia on the pharmacodynamics
on both bolus dosage and continuous infusion should
have been investigated consecutively in all our patients.
However, this would have been time consuming and
logistically impossible to carry out in our clinical setting.
It is logical to assume that the duration of the expo-
sure to nitrous oxide has an effect but there is no defini-
tive evidence. The more likely explanation is that
nitrous oxide has only a minor effect, if any, on the neu-
romuscular action of muscle relaxants. While looking at
the scattergram of the individual Iss values in the cur-
rent study (Figure 2), it is plausible to conclude that the
effect of nitrous oxide on cisatracurium pharmacody-
namics is negligible, as was the case in our rocuronium
study, and has no clinical significance. The same infor-
mation is provided also by the 95% confidence intervals
of the differences in mean Iss and Iss/IBW values. We
conclude that nitrous oxide does not affect the infusion
requirements of cisatracurium to a clinically significant
degree.
Conclusions
Nitrous oxide does not affect cisatracurium demand
when using closed-loop computerized infusion of the
muscle relaxant with the aim of maintaining a stable
90% neuromuscular block.
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